medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2018, Number 4

<< Back

Acta Med 2018; 16 (4)

Obesidad, síndrome metabólico, esteatohepatitis no alcohólica y su diagnóstico con elastografía por ultrasonido

Lozano ZH, González SN

Language: Spanish
References: 29
Page: 382-387
PDF size: 425.83 Kb.


Text Extraction

No abstract.


REFERENCES

  1. http://www.who.int/gho/publications/world_health_statistics/2014/es/

  2. Metabolic syndrome. National Institutes of Health (NIH). Available in: http://nih.gov/metabolic syndrome/index. Udated U2015

  3. Centers for Disease Control and Prevention website http://www.cdc.gov/hepatitis/index.htm Updated Sept 2014.

  4. Cifras de sobrepeso y obesidad en México-ENSANUT MC 2016. http://oment.gob.mx. Dic 2016.

  5. Younossi ZM, Koenig AB, Abdelarif D et al. Global epidemiology of nonalcoholic fatty liver disease –meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. 2016; 64: 73-84.

  6. Diehl AM, Day C. Cause, pathogenesis and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017; 377: 2063-2072.

  7. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013; 10 (11): 686-690.

  8. Wong VW, Wong GL, Choi PC. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010; 59: 969-974.

  9. Bhala N et al. The natural history of non-alcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011; 54: 1208-1216.

  10. Yeh MM et al. Pathological features of fatty liver disease. Gastroenterology. 2014; 47: 754-764.

  11. Williams CD et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroentology. 2011; 140: 124-131.

  12. Adams LA, Harmsen S, St Sauver JL et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol. 2010; 105: 1567-1573.

  13. Angulo P, Machado DW, Dihel AM et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015; 149: 389-397.

  14. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontrigliceride fatty acid metabolites. Hepatology. 2010; 52: 774-788.

  15. Schupan D, Schattenberg JM. Non-alcoholic steatohepatitis pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013; 13: 68-76.

  16. Neuschwander-Tetri BA, Lomba R, Sanyal AJ et al. NASH clinical research network. Farmesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicenter randomized placebo-controlled trial. Lancet. 2015; 385: 956-965.

  17. Koehler EM, Schouten JN, Hansen BE et al. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in population-based study. Clin Gastroenterol Hepatol. 2013; 11: 1201-1204.

  18. Poynard T. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HVC FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004; 3: 8.

  19. Srinivasa AB, Wells ML, Teytelboym OM et al. Elastography in chronic liver disease: modalities, techniques, limitations and future directions. Radiographics. 2016; 36: 1987-2006.

  20. Picó Aliaga SD, Muro VD, García-Martí y cols. La elastografía mediante técnica ARFI es eficaz en la detección de fibrosis hepática en el niño. Radiología. 2015; 57: 314-320.

  21. Ko SY, Kim EK, Sung JM et al. Diagnostic performance of ultrasound and ultrasound elastography with respect to physician experience. Ultrasound Med Biol. 2014; 40: 854-863.

  22. Musso G, Cassader M, Rossina F et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomized trials. Diabetologia. 2012; 55: 885-904.

  23. Vilar-Gomez E, Martinez-Perez Y, Calzadilla BL et al. Weight loss through lifestyle modifucation significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015; 149: 367-378.

  24. Marchesini G, Brizi M, Bianchi G et al. Metformin in non-alcoholic steatohepatitis. Lancet. 2001; 358: 893-894.

  25. Musso G, Gambino R, Cassader M et al. A meta-analysis of randomized trials for the treatment on non-alcoholic fatty liver disease. Hepatology. 2010; 52: 79-104.

  26. Corey KE, Klebanoff MJ, Tramontano AC et al. Screening for nonalcoholic steatohepatitis in individuals with type 2 Diabetes: a cost-effectiviness analysis. Dig Dis Sci. 2016; 61: 2108-2117.

  27. Schwimmer JB, Behling C, Newbury R et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005; 42: 641-649.

  28. Schwimmer JB, Deustch R, Kahen T et al. Prevalence of fatty liver in children and adolecents. Pediatric. 2006; 118: 1388-1393.

  29. Silva AM, Grimm RC, Glaser KJ et al. Magnetic resonance elastography: evaluation of new inversion algorithm and quantitative analysis method. Abdom Imaging. 2015; 40 (4): 810-817.




2020     |     www.medigraphic.com